Share

Publication of 2022 EORTC Annual Report

This comprehensive report collects the most relevant and up-to-date information on EORTC’s activities demonstrating the continuous progress achieved in the field of clinical cancer research by our organisation.

The 2022 edition is a very special one, as last year marked a significant milestone for our organisation which celebrated its 60th anniversary. Today, EORTC is a well-renowned independent, academic and multidisciplinary clinical cancer research organisation, whose network encompasses over 3,400 collaborators from diverse disciplines across more than 50 countries. 22,000 patients continue to be followed on a yearly basis and the EORTC clinical study database now contains outcome data for over 210,000 cancer patients.

As well, EORTC contributes actively to the evolving eco-systems in oncology whether addressing methodological, scientific or regulatory challenges. EORTC remains also very active in education for clinical research-related science.

This year we celebrate our past, but we also recognise the importance of continually evolving and adapting to meet future challenges and keep building on our distinguished record of scientific achievements.
– Dr. Denis Lacombe, EORTC CEO.

On behalf of EORTC, we would like to express our sincere gratitude to all the people who support, collaborate, and believe in the mission of EORTC to improve the survival and quality of life of cancer patients. 

Back to news list

Related News

  • EORTC calls for a balanced and feasible European Health Data Space (EHDS)

  • Professor Benjamin Besse becomes President of EORTC

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026